Personalized OncoGenomics Program in British Columbia Using Genome Sequencing to Guide Treatment for Advanced and Metastatic Cancers

What this Trial Is About

Researchers are investigating how the genetic diversity of cancers affects treatment by using full genome sequencing to identify specific genetic changes driving cancer growth. The study focuses on patients with metastatic or incurable cancers, aiming to match each individuals cancer profile with targeted therapies based on their unique molecular signatures. This personalized approach hopes to guide chemotherapy choices and improve understanding of cancer genetics across different patients. Participants will undergo biopsies to collect fresh tumor samples and blood for normal DNA comparison. Comprehensive DNA and RNA sequencing is performed, followed by detailed bioinformatic analysis to detect mutations and gene expression changes that may serve as treatment targets. The study team regularly reviews genomic data to recommend possible systemic therapies and match patients to clinical trials when available. This program has evolved over several phases and is integrated with clinical trials to apply genomic findings to cancer care. Throughout the study, participants will provide tumor biopsies, blood samples, and archival tissue if available. Researchers analyze genetic data and discuss findings weekly to guide treatment decisions. The study measures the impact of genomic data on clinical decision-making and catalogs cancer genomes over five years. Participation includes ongoing monitoring and data sharing with research collaborators, with a total duration aligned with the programs long-term goals.

Personalized Oncogenomics (POG) Program of British Columbia